BH-501284 demonstrated high potency (median IC50 of 0.83 nM) and prolonged residence time (>54 hours) in KRAS-mutant cell lines, offering ...
In this valuable study, the authors develop new approaches to investigate mRNA imprinting, a phenomenon in which RNA-protein complexes form in the nucleus to influence the fate of transcripts in the ...
SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company pioneering rationally designed molecular glue ...
The gene editing treatment targets the relatively common 1717-1G>A splicing mutation, which does not respond to many current CF therapies.
New program matches top researchers with expert service providers trained to offer a comprehensive suite of Shasta® ...
"RNA modifications are central to how cells respond to their environment," said Gudrun Stengel, Ph.D., Chief Executive Officer of Alida Biosciences. "With EpiPlex Tri-Mod, we move beyond method ...
Pharmaceutical Technology on MSN
The innovators working to make in vivo cell therapy a reality
As in vivo cell therapies enter clinical trials, suppliers tackle the technical and logistical barriers to commercial viability.
Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice ...
(NEXSTAR) – An advance in vaccine technology is showing promise toward fighting the second-most common cause of death in the United States, cancer. Scientists are working on developing mRNA vaccines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results